About
News, Events & Presentations
Press Releases | Events Calendar | Presentations

Keyword Search
 
2017 | 2016 | 2015 | 2014
DateTitle 
12/19/16Fibrocell Announces Leadership ChangesPrinter Friendly Version
11/10/16Fibrocell Appoints Alfred T. Lane, MD, Chief Medical AdvisorPrinter Friendly Version
11/03/16Fibrocell Reports Third Quarter 2016 Financial Results and Recent Operational HighlightsPrinter Friendly Version
10/31/16Fibrocell to Host Conference Call and Webcast on Thursday, November 3, 2016 to Discuss Third Quarter 2016 Financial Results and Recent Operational HighlightsPrinter Friendly Version
09/29/16Fibrocell to Present at 2016 Cell & Gene Meeting on the MesaPrinter Friendly Version
09/19/16Fibrocell Completes Enrollment in NC1+ Cohort of Phase I/II Clinical Trial of FCX-007 for Treatment of Recessive Dystrophic Epidermolysis BullosaPrinter Friendly Version
09/08/16Fibrocell Announces Closing of $18 Million Private PlacementPrinter Friendly Version
08/09/16Fibrocell Announces Convertible Debt and Warrant Financing of Up to $25 MillionPrinter Friendly Version
08/08/16Fibrocell Announces Proposed Public Offering of Common Stock and WarrantsPrinter Friendly Version
08/04/16Fibrocell Reports Second Quarter 2016 Financial Results and Recent Operational HighlightsPrinter Friendly Version
07/28/16Fibrocell to Host Conference Call and Webcast on Thursday, August 4, 2016 to Discuss Second Quarter 2016 Financial Results and Recent Operational HighlightsPrinter Friendly Version
07/27/16Fibrocell Announces First Subjects Enrolled in Phase I/II Clinical Trial of FCX-007 for Treatment of Recessive Dystrophic Epidermolysis BullosaPrinter Friendly Version
07/07/16Fibrocell to Present at Cantor Fitzgerald’s 2nd Annual Healthcare ConferencePrinter Friendly Version
06/29/16Fibrocell Expects Significant Cost Savings from Wind-Down of azficel-T OperationsPrinter Friendly Version
06/13/16Fibrocell Announces Initiation of Patient Recruitment in Phase I/II Clinical Trial of FCX-007 for Treatment of Recessive Dystrophic Epidermolysis BullosaPrinter Friendly Version
06/08/16Fibrocell Reports Phase II azficel-T Trial for Treatment of Vocal Cord Scarring Did Not Meet Primary EndpointsPrinter Friendly Version
05/05/16Fibrocell Reports First Quarter 2016 Financial Results and Operational HighlightsPrinter Friendly Version
04/28/16Fibrocell to Host Conference Call and Webcast on Thursday, May 5, 2016 to Discuss First Quarter 2016 Financial Results and Recent Operational HighlightsPrinter Friendly Version
04/25/16Fibrocell Receives Orphan Drug Designation from the FDA for FCX-013 for the Treatment of Localized SclerodermaPrinter Friendly Version
04/21/16Fibrocell Announces Last Patient Visit for Primary Endpoint Analysis in Phase II Clinical Trial of azficel-T for the Treatment of Vocal Cord ScarringPrinter Friendly Version
04/18/16Fibrocell and Intrexon Announce Allowance to Commence Phase I/II Trial for FCX-007 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)Printer Friendly Version
03/15/16Fibrocell to Present at the Alliance for Regenerative Medicine’s 4th Annual Cell & Gene Therapy Investor DayPrinter Friendly Version
03/10/16Fibrocell Reports Fourth Quarter and Full Year 2015 Financial Results and Operational HighlightsPrinter Friendly Version
03/08/16Fibrocell to Present at 28th Annual ROTH ConferencePrinter Friendly Version
03/03/16Fibrocell to Report Fourth Quarter and Full Year 2015 Financial Results and Operational Highlights, and Host Conference Call and Webcast on Thursday, March 10, 2016Printer Friendly Version
02/16/16Fibrocell to Present at RBC Capital Markets 2016 Global Healthcare ConferencePrinter Friendly Version
01/27/16Fibrocell Highlights Recent Pipeline AccomplishmentsPrinter Friendly Version
01/04/16Fibrocell and Intrexon Announce Collaboration to Address Chronic Inflammatory and Degenerative Diseases of the JointPrinter Friendly Version



Printer Friendly Version E-mail this page RSS E-mail Alerts Download Financial Tear Sheet